Free Alerts   Login
Health Care › Industrial Instruments For Measurement, Display, And Control

MLAB Stock Price Correlated With Mesa Laboratories Financials

MLAB Stock Price vs. Quarterly
MLAB
Income Statement
Cash Flow
Balance Sheet

MLAB Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

MLAB Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

MLAB Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
845,885 sh
40,138 sh
5%
$88,623
$3,962
Conestoga Capital Advisors
578,463 sh
2,240 sh
0%
$60,606
-$13,439
Vanguard Group
370,278 sh
7,274 sh
2%
$38,794
$654
Royce & Associates Lp
269,645 sh
103,623 sh
62%
$28,251
$10,807
Morgan Stanley
261,324 sh
17,971 sh
7%
$27,378
$1,810
Ranger Investment Management, L.P.
226,682 sh
2,689 sh
1%
$23,749
$214
State Street
198,407 sh
14,874 sh
8%
$20,787
$1,503
Geneva Capital Management
189,529 sh
-5,683 sh
-3%
$19,857
-$654
Dimensional Fund Advisors
127,235 sh
-764 sh
-1%
$13,330
-$118
Eagle Asset Management
115,277 sh
3,298 sh
3%
$12,078
$312
Geode Capital Management
111,115 sh
6,026 sh
6%
$11,643
$600
Kennedy Capital Management.
107,067 sh
-2,429 sh
-2%
$11,217
-$288
Glenmede Na
90,883 sh
-3,454 sh
-4%
$9,522
-$390
Northernrp
81,518 sh
-13,385 sh
-14%
$8,540
-$1,432
Granahan Investment Management/Ma
71,886 sh
8,013 sh
13%
$7,531
$820
Goldman Sachs Group
66,119 sh
-21,056 sh
-24%
$6,927
-$2,232
BOONE CAPITAL MANAGEMENT
64,064 sh
64,064 sh
NEW
$6,712
$6,712
Bank Of New York Mellon
61,094 sh
4,835 sh
9%
$6,402
$491
Ameriprise Financial
54,600 sh
5,054 sh
10%
$5,720
$514
Raymond James & Associates
47,019 sh
-20,407 sh
-30%
$4,926
-$2,158
COMPANY PROFILE
Note 1. Description of Business and Summary of Significant Accounting Policies

Description of Business

In this Annual Report on Form 10 -K, Mesa Laboratories, Inc., a Colorado corporation, together with its subsidiaries is collectively referred to as “we,” “us,” “our,” the “Company” or “Mesa Labs.”

We are a multinational manufacturer, developer, and seller of quality control products and services, many of which are sold into niche markets that are driven by regulatory requirements. We have manufacturing operations in North America and Europe and our products are marketed by our sales personnel in North America, Europe, and Asia, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross margins.

As of March 31, 2021, we managed our operations in four reportable segments, or divisions. Our Sterilization and Disinfection Control division manufactures and sells biological, cleaning, and chemical indicators which are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The division also provides testing and laboratory services, mainly to the dental industry. Our Instruments division designs, manufactures, and markets quality control hardware and disposable products utilized in the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, and environmental air sampling industries. During the year ended March 31, 2020, we added a new reportable segment: Biopharmaceutical Development as a result of our acquisition of Gyros Protein Technologies Holding AB ("GPT" or the "GPT acquisition"), which is discussed further in Note 4."Significant Transactions." Our Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Immunoassays and peptide synthesis solutions accelerate the discovery, development, and manufacturing of biotherapeutic drugs. Our Continuous Monitoring division designs, develops, and markets systems which are used to monitor various environmental parameters such as temperature, humidity, and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments.  Non-reportable operating segments (including our Cold Chain Packaging division which ceased operations during the year ended March 31, 2020) and unallocated corporate expenses are reported within Corporate and Other.

Principals of Consolidation and Basis of Presentation Our Consolidated Financial Statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and include our accounts and wholly owned subsidiaries after elimination of all intercompany accounts and transactions. GPT results are consolidated with Mesa's financial statements beginning November 1, 2019, the first full day following the acquisition. Prior period results have not been recast and are therefore not comparable with the year ending March 31, 2021.

Management Estimates The preparation of our Consolidated Financial Statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our Consolidated Financial Statements and accompanying notes. Actual results could differ from our estimates under different assumptions or conditions.

Summary of Significant Accounting Policies

Foreign Currency Exchange rate adjustments resulting from foreign currency transactions are recognized in net earnings, whereas effects resulting from the translation of financial statements are reflected as a component of accumulated other comprehe

Free historical financial statements for Mesa Laboratories Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 51 quarters since 2011. Compare with MLAB stock chart to see long term trends.

Data imported from Mesa Laboratories Inc SEC filings. Check original filings before making any investment decision.